[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633229":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":30,"collaborators":10,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":45,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"JW Pharmaceutical","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Pitavastatin\u002FEzetimibe Group",null,"Patients with dyslipidemia and metabolic syndrome who are prescribed a fixed-dose combination of Pitavastatin and Ezetimibe",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"EUNJU KIM","CONTACT","82-2-840-6983","kej@jwhealthcare.com",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":10,"cosmosGeoPoint":24,"geoPoint":29,"contacts":10},"Chungnam National University Hospita","RECRUITING","Daejeon","South Korea",{"type":25,"coordinates":26},"Point",[27,28],127.38493,36.34913,{"lat":28,"lon":27},{"type":31,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100633229","efficacy-and-safety-of-pitavastatinezetimibe-in-dyslipidemia-patients-with-metabolic-syndrome-an-observational-study-100633229",false,"NCT07523971","Efficacy and Safety of Pitavastatin\u002FEzetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study","A Multi-center, Open-label, Observational Study to Evaluate the Efficacy and Safety of Pitavastatin\u002FEzetimibe Tablets in Patients With Dyslipidemia Who Also Have Metabolic Syndrome","PIVOT","Inclusion Criteria:\n\n1. Age 19 years old at the time of written informed consent\n2. Subjects diagnosed with dyslipidemia and metabolic syndrome\n3. Subjects who had no treatment history with lipid regulators within 4 weeks prior to Visit1 or who had insufficient therapeutic effects from 8 weeks of treatment with lipid regulators using the same dosage and administration\n4. Subjects who meet the following LDL-C levels according to the classification of cardiovascular disease risk groups\\* at Visit 1 or who are planned to be treated with Pitavastatin\u002FEzetimibe Tablets based on the judgment of the investigator\n5. Subjects who voluntarily sign the informed consent form for study participation\n\nExclusion Criteria:\n\n1. Individuals for whom Pitavastatin\u002FEzetimibe Tablets is contraindicated as specified in the label's Precautions for Use\n2. Individuals who were treated with other investigational products (IP) or investigational devices within 4 weeks prior to participation in the present study or who are expected to have such treatment during the present study\n3. Individuals who are considered to have difficulty participating in the study for other reasons based on the judgment of the investigator","ALL","19 Years",{"count":43,"type":44},10000,"ESTIMATED","1 Year","OBSERVATIONAL","The purpose of this study is to evaluate the efficacy and safety of Pitavastatin\u002FEzetimibe tablets (a fixed-dose combination of Pitavastatin and Ezetimibe) in patients with dyslipidemia who also have metabolic syndrome in a real-world clinical setting.\n\nAs this is an observational study, participants will be treated according to the investigator's medical judgment and routine clinical practice. The study aims to observe the changes in low-density lipoprotein cholesterol (LDL-C) levels from baseline to 24 weeks and 48 weeks of treatment. Safety will also be assessed by monitoring any adverse events occurring during the 48-week observation period.",[49],"Dyslipidemias",[51],"Metabolic Syndrome","2026-04-05",{"date":54,"type":55},"2026-04-13","ACTUAL",{"date":57,"type":55},"2025-06-25",{"date":59,"type":44},"2027-06",{"name":5,"class":6},1]